Please check your internet connection and try again.
# Rizatriptan
## Overview
Rizatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used for the acute treatment of migraine. It exhibits faster absorption and potentially higher efficacy than some earlier-generation triptans. Available as oral tablets and orally disintegrating tablets (ODT).
## Primary Indications
Acute treatment of migraine attacks with or without aura in adults and pediatric patients (6–17 years). Not indicated for migraine prophylaxis or management of hemiplegic or basilar migraine.
## Adult Dosing
* **Standard dose:** 5 mg or 10 mg at onset of migraine.
* **Dosing frequency:** If symptoms persist, a second dose may be taken no sooner than 2 hours after the first.
* **Maximum daily dose:** 30 mg in a 24-hour period.
## Pediatric Dosing
* **Weight < 40 kg:** 5 mg single dose.
* **Weight ≥ 40 kg:** 10 mg single dose.
* **Note:** Efficacy and safety for repeat dosing in patients < 18 years have not been adequately established. Consult local institutional protocols regarding repeat dosing in pediatric populations.
## Dose Adjustments
* **Hepatic Impairment:** Reduce starting dose to 5 mg for mild-to-moderate impairment. Avoid in severe impairment.
* **Renal Impairment:** No specific adjustment required.
* **Concomitant Propranolol:** Reduce dose to 5 mg (max 15 mg/24 hours) due to increased rizatriptan plasma concentrations.
## Contraindications
* History of ischemic heart disease, coronary artery vasospasm (Prinzmetal’s angina), or MI.
* History of stroke or transient ischemic attack (TIA).
* Peripheral vascular disease or ischemic bowel disease.
* Uncontrolled hypertension.
* Administration within 24 hours of another 5-HT1 agonist or ergot-type medication.
* Administration within 2 weeks of MAO inhibitor therapy.
* Severe hepatic or renal impairment.
## Adverse Effects
* **Common:** Dizziness, somnolence, paresthesia, and sensations of tightness, pressure, or heaviness in the chest/neck/throat (usually non-cardiac).
* **Rare but serious:** Myocardial infarction, arrhythmias, coronary artery vasospasm, and serotonin syndrome (especially when combined with SSRIs/SNRIs).
## Key Drug Interactions
* **Propranolol:** Increases rizatriptan levels (requires dose reduction).
* **MAO Inhibitors:** Risk of severe serotonin syndrome; contraindicated.
* **SSRIs/SNRIs:** Potential risk for serotonin syndrome; monitor for symptoms (agitation, tremor, hyperreflexia).
* **Ergot alkaloids:** Increased risk of prolonged vasospastic reactions; refrain from concurrent use within 24 hours.
## Monitoring
* Assess for cardiovascular symptoms (chest pain, shortness of breath) during the first dose in patients with risk factors.
* Monitor for signs of serotonin syndrome if used with serotonergic agents.
* Evaluate frequency of use to prevent medication overuse headache (MOH).
## Clinical Pearls
* **Administration:** ODT formulation does not require water; the blister pack should be dry when peeling to remove the tablet.
* **Efficacy:** Effectiveness is significantly improved when the drug is taken at the onset of migraine pain.
* **Medication Overuse Headache:** Discourage use for more than 10 days per month to avoid secondary chronic migraine.
* **Safety warning:** Chest symptoms are common and usually benign, but if symptoms indicate cardiac ischemia, discontinue use and evaluate immediately.
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice guidelines and drug information evolve; always verify specific dosing and contraindications against current institutional protocols and the manufacturer's official full prescribing information (package insert) before prescribing or administering medication.
